Direct access transcatheter mitral annuloplasty with a sutureless and adjustable device: preclinical experience by Maisano, Francesco et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2012
Direct access transcatheter mitral annuloplasty with a sutureless and
adjustable device: preclinical experience
Maisano, Francesco; Vanermen, Hugo; Seeburger, Joerg; Mack, Michael; Falk, Volkmar; Denti, Paolo;
Taramasso, Maurizio; Alfieri, Ottavio
Abstract: OBJECTIVES: The aim of the study was to evaluate the technical feasibility and performance
of a transcatheter mitral annuloplasty system. METHODS: Adult swines (n = 15) underwent left thora-
cotomy through the 4th-5th intercostal space. A transcatheter device (CardioBand, Valtech-Cardio Ltd)
was introduced through an 18F sheath through the left atrium and attached to the annulus between the
posterior and anterior commissures using echocardiographic and fluoroscopic guidance, on the beating
heart. The sutureless device was implanted using a steerable delivery system to deploy sequential fix-
ation elements. Following implantation, the device length was adjusted on the beating heart to reduce
the intercommissural and septolateral dimension, under echocardiographic guidance. Finally, the flexible
adjustment tool was withdrawn from the working sheath and the atrial purse-string closed. All but five
animals were sacrificed acutely by intent, while the others were sacrificed at 90 days. RESULTS: All
animals survived the acute implant. One animal died at the third post-operative day due to bleeding.
The annuloplasty system was successfully implanted in all animals. A mean of 12 ± 3 fixation elements
were deployed. The band length was reduced up to 20% after implantation in each animal. At necropsy,
the location of the implant was within a few millimetres of the annulus (3.5 ± 4 mm). In three animals,
fixation elements were implanted inadvertently in the leaflets, but no coronary lesions were observed. All
animals survived the acute implant. One animal died on the third post-operative day due to bleeding.
In the four long-term survivors, the implanted annuloplasty device showed satisfactory healing and no
ring dehiscence. CONCLUSIONS: Transcatheter minimally invasive, beating-heart implantation of an
adjustable annuloplasty band is feasible in the animal model. This approach may be an alternative to
open surgical procedures in high-risk patients.
DOI: https://doi.org/10.1093/ejcts/ezs069
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-72680
Journal Article
Published Version
Originally published at:
Maisano, Francesco; Vanermen, Hugo; Seeburger, Joerg; Mack, Michael; Falk, Volkmar; Denti, Paolo;
Taramasso, Maurizio; Alfieri, Ottavio (2012). Direct access transcatheter mitral annuloplasty with a
sutureless and adjustable device: preclinical experience. European Journal of Cardio-Thoracic Surgery,
42(3):524-529.
DOI: https://doi.org/10.1093/ejcts/ezs069
Direct access transcatheter mitral annuloplasty with a sutureless
and adjustable device: preclinical experience†
Francesco Maisanoa,*, Hugo Vanermenb, Joerg Seeburgerc, Michael Mackd, Volkmar Falkd,e, Paolo Dentia,
Maurizio Taramassoa and Ottavio Alﬁeria
a Department of Cardiac Surgery, San Raffaele Hospital, Milan, Italy
b Department of Cardiothoracic Surgery, OLV Hospital, Aalst, Belgium
c Department of Cardiothoracic Surgery, University of Leipzig Heart Center, Leipzig, Germany
d Heart Hospital Baylor Plano, Dallas, TX, USA
e University of Zürich, Zürich, Switzerland
* Corresponding author. Department of Cardiac Surgery, San Raffaele University Hospital, Via Olgettina 60, 20132 Milan, Italy. Tel: +39-02-26437111;
fax: +39-02-26437125; e-mail: francesco.maisano@hsr.it (F. Maisano).
Received 5 September 2011; received in revised form 6 December 2011; accepted 12 December 2011
Abstract
OBJECTIVES: The aim of the study was to evaluate the technical feasibility and performance of a transcatheter mitral annuloplasty
system.
METHODS: Adult swines (n = 15) underwent left thoracotomy through the 4th–5th intercostal space. A transcatheter device
(CardioBand, Valtech-Cardio Ltd) was introduced through an 18F sheath through the left atrium and attached to the annulus between
the posterior and anterior commissures using echocardiographic and ﬂuoroscopic guidance, on the beating heart. The sutureless
device was implanted using a steerable delivery system to deploy sequential ﬁxation elements. Following implantation, the device
length was adjusted on the beating heart to reduce the intercommissural and septolateral dimension, under echocardiographic guid-
ance. Finally, the ﬂexible adjustment tool was withdrawn from the working sheath and the atrial purse-string closed. All but ﬁve animals
were sacriﬁced acutely by intent, while the others were sacriﬁced at 90 days.
RESULTS: All animals survived the acute implant. One animal died at the third post-operative day due to bleeding. The annuloplasty
system was successfully implanted in all animals. A mean of 12 ± 3 ﬁxation elements were deployed. The band length was reduced up
to 20% after implantation in each animal. At necropsy, the location of the implant was within a few millimetres of the annulus (3.5 ± 4
mm). In three animals, ﬁxation elements were implanted inadvertently in the leaﬂets, but no coronary lesions were observed. All
animals survived the acute implant. One animal died on the third post-operative day due to bleeding. In the four long-term survivors,
the implanted annuloplasty device showed satisfactory healing and no ring dehiscence.
CONCLUSIONS: Transcatheter minimally invasive, beating-heart implantation of an adjustable annuloplasty band is feasible in the
animal model. This approach may be an alternative to open surgical procedures in high-risk patients.
Keywords: Mitral regurgitation • Transcatheter mitral repair • Mitral annuloplasty
INTRODUCTION
Mitral valve annuloplasty (MVA) is a routine procedure during
open heart valve repair surgery. Ring annuloplasty increases the
durability of the repair due to increase in coaptation and reduc-
tion in structural stress on valve tissue [1–3].
Recently, transcatheter mitral repair is emerging as an alterna-
tive therapy in high-risk patients who are not referred for
surgery [4]. Leaﬂet repair with the MitraClip (Abbott Vascular,
Menlo Park, CA, USA) is currently available in Europe for clinical
use [5]. Miscellaneous solutions are under development for
annular repair.
CardioBand™ (ValtechCardio, OrYehuda, Israel) is a transcath-
eter MVA system designed to implant a Dacron posterior annu-
loplasty band with a sutureless technique, on the beating heart,
under echocardiographic and ﬂuoroscopic guidance.
We describe the initial preclinical experience with the transat-
rial version of the device, which is designed to implant the
annuloplasty band via a minimally invasive, direct access ap-
proach to the left atrium.
METHODS
Fifteen animals, weighing 70–90 kg, underwent the CardioBand
procedure. Under general anaesthesia, a muscle sparing left
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thoracotomy in the 4th or 5th intercostal space was performed,
avoiding damage to the latissimus dorsi muscle, and the pericar-
dial sac was incised in T-fashion, exposing the left atrium.
Prophylactic Lidocaine 100 mg intravenously was administered
prior to any manipulation of the heart. Pre-operative measure-
ments of the mitral valve with epicardial echocardiography (HP
sonos 1000, Philips Andover, MA, USA) were performed. A purse
string was then placed in the middle of the left appendage to
insert the CardioBand delivery system. Heparin was administered
at 100 units/kg and repeated if the activated clotting time was
shorter than 300 s until the delivery system was in the left atrium.
The CardioBand™ system
The CardioBand delivery system (Fig. 1b) is a steerable device
carrying the implant (Dacron band) and the anchors (metallic
helices). The implanted band is then contracted using an adjust-
ment tool (Fig. 1a). Access to the mitral valve was gained by
inserting a speciﬁcally designed 18F introducer sheath (Fig. 1c)
with sealing valve through the wall of the left atrium, within a
purse string. A protection cover envelops the implant during in-
sertion of the delivery system through the introducer. A knob at
the end of the device controls the distal steerable tip for man-
oeuvring the implant towards the annulus. The ﬁrst anchor was
positioned at the posteromedial commissure (Fig. 2a). This target
was located by epicardial echocardiography using both short-
and long-axis views. Great care was taken to exclude the leaﬂet
contact with the tip of the delivery system, and to maintain a
perpendicular aim of the delivery system related to the annular
plane, to allow penetration of the anchors in the base of the left
ventricle. The anchor implant is reversible until the anchor is
completely delivered and released from the delivery system.
Once the anchor is fully implanted, an advance button releases
the implant at constant lengths. An anchor magazine, which
contains up to 15 helical anchors, is used to sequentially deliver
the anchors to ﬁxate the ring to the tissue. The following anchor
implants continued in counter clock-wise fashion (Fig. 2b) from
the posteromedial commissure, towards the antero-lateral com-
missure, along the annular perimeter under echocardiographic
guidance, and tactile feedback (necessary from the mid-portion
of the posterior leaﬂet to the antero-lateral commissure due to
poor imaging). Once deployment of the implant was completed,
another button disconnected the implant from the delivery
system and connected it to the adjustment tool (Fig. 2c).
Rotating the adjustment roller contracts or expands the band on
the beating heart under echocardiographic guidance (Fig. 2d).
Since healthy animals without mitral regurgitation (MR) were in
use in this study, maximal contraction was performed by a con-
stant length (up to 20%), as opposed to contraction for the
purpose of MR ﬁxation. Once the desired contraction was
obtained, the implant was released from the adjustment tool
Figure 1: The CardioBand delivery system (b). The implanted band is then
contracted using an adjustment tool (a). The speciﬁcally designed 18F intro-
ducer sheath to approach the mitral valve (c).
Figure 2: The ﬁrst anchor is positioned at the posteromedial commissure (a). The following anchor implants continued in counter clock-wise fashion (b).
Disconnection of the implant from the delivery system and connection to the adjustment tool (c). Adjustment of the band on the beating heart under echocardio-
graphic guidance (d).
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and the delivery system was removed from the 18F sheath.
Finally, the sheath was removed and the purse string tied. The
chest wall was then closed as usual. Post-operative antibiotic and
analgesia therapy was continued during follow-up for up to 5
days.
Follow-up
Ten animals were sacriﬁced at the end of the acute implant,
while ﬁve animals were kept alive and followed-up for a period
up to 90 days post index procedure. Assessment of general clin-
ical signs accompanied by haematological evaluation was per-
formed pre-procedurally and during the course of the follow-up
period. In addition, ultrasound echocardiography was performed
for dynamic mechanical function, blood ﬂow and heart anatom-
ical measures (axis), at baseline, immediately after implantation,
at 15 and 30 days post-implantation and before sacriﬁce (at 60–
90 days). At the end of the follow-up period, all surviving
animals were euthanized and the hearts were explanted for
assessment.
RESULTS
All animals survived the acute implant. One animal died at the
third post-operative day due to bleeding from the internal
mammary artery during thoracotomy. The annuloplasty system
was implanted in all animals. A mean of 13 ± 2 ﬁxation elements
were deployed. Implant device time (time from insertion of the
device in the left atrium to the deployment of the last ﬁxation
element) was 23 ± 8 min (range 15–40 min). In one animal, ven-
tricular ﬁbrillation induced by heart manipulation necessitated
electrical deﬁbrillation, while extrasystolic beats were common
during helix anchor deployment. No animal required post-
implant inotropic support. In all animals, echocardiographic
imaging was insufﬁcient for guiding the procedure in the antero-
lateral half of the posterior annulus; therefore, implantation was
guided by a combination of epicardial echocardiography and
manual palpation of the annulus. The band length was reduced
up to 20% after implantation in each animal (Fig. 3a and b). As a
result of band implantation, valve area, intercommissural and
septolateral distance of the annulus were signiﬁcantly reduced
(Table 1). The quality of the image prevented a measurement of
coaptation length. Prior to euthanasia, 90-day transthoracic
echocardiography demonstrated no or trace MR in all four
survivors, with no ventricular dysfunction. At necropsy, the loca-
tion of the implant was within a few millimetres of the annulus
(3.5 ± 4 mm). In three acute experimental animals, ﬁxation ele-
ments were implanted inadvertently in the base of the leaﬂets,
but no coronary lesions were observed. In all cases, the mis-
placed implants were located in the antero-lateral portion of the
posterior annulus, in the area where imaging was poor. In the
four long-term survivors, the implanted annuloplasty device
showed satisfactory healing and no major ring dehiscence. Four
animals survived the chronic follow-up time. At gross anatomy
examination of the CardioBand, healing of the device was excel-
lent, with tissue in-growth and endocardial covering of the
devices. In addition, gross examination did not show migration
of any of the anchors or damage to them or to the tissue as a
result of contraction.
The implant did not cause any thrombus formation, toxicity or
hyperplasia/hypertrophy.
Although minimal areas of implant dehiscence were observed,
no device defects were observed and the implant seemed to be
ﬁrmly attached to the annulus. No damage was caused to native
mitral annulus or to adjacent structures except for some adhe-
sions with the posterior leaﬂet, which did not seem to affect the
function of the mitral valve. Gross anatomy ﬁndings of animals
implanted with CardioBand system revealed that the implant
was well healed and covered by ﬁbrous tissue (Fig. 4a and b).
DISCUSSION
Our data demonstrate that it is feasible to implant a sutureless
and adjustable MVA band with a transcatheter approach, under
beating heart conditions, in the animal model.
Although the procedure has been successful in the animal
model, several challenges have to be overcome before proceed-
ing to clinical application.
Sutureless ﬁxation
The CardioBand system is a sutureless ring for MVA. Particularly
when considering minimally invasive surgery, suturing and knot-
tying are time consuming. The CardioBand system includes a
proprietary method to ﬁxate the annuloplasty Dacron band to
the annular tissue using multiple helix anchors. The device has
been designed for transcatheter beating heart use, but has also
been used in a minimally invasive open-heart approach
Figure 3: Band length before the adjustment (a); reduction in the band length up to 20% after the adjustment (b).
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environment in the animal model. Although complete annulo-
plasty is probably more effective than posterior band annulo-
plasty, the latter solution was preferred for safety reasons, since
the risk of aortic valve injury is a potential issue in a transcath-
eter approaches, especially given the problems with the imaging
quality in the animal model. However, our acute data conﬁrm
that posterior annuloplasty alone is able to determine a signiﬁca-
tive reduction in annular areas and diameters.
The concept of using a helix screw anchors is commonly
applied for pacemaker and deﬁbrillator leads ﬁxation [6, 7]. The
helix anchor is designed to enable a safe and precise attachment
of the annuloplasty ring to the soft tissue of the mitral annulus.
In addition, the helix screw concept allows repositionability and
retrievability of the anchors. Replacing the suturing technique
with a minimally invasive off-pump mitral valve repair, using
helix anchors, was introduced and tested a decade ago by
Morales et al. [8]. Their tests included in vitro simulations of
haemodynamic and mechanical consequences of screw implant-
ation, in explanted human mitral valves. Next, the screw was
tested in vivo in dogs. The authors reported no screw detach-
ment or migration from the mitral valves less than 6.8 million
cycles. Postoperative echocardiograms in two dogs demon-
strated consistent coaptation, no screw migration, no clotting
and no regurgitation or stenosis. In an animal sacriﬁced after
12 weeks, the screw was fully integrated in the mitral soft tissues.
Histological analysis of the implanted CardioBand devices
showed that the fabric and metallic components were incorpo-
rated in a mild-to-moderate ﬁbrous pannus of relatively homo-
geneous thickness.
No dehiscence was observed in the chronic animal hearts.
The potential risk of dehiscence is related to sufﬁcient penetra-
tion of the ﬁxation elements into the tissue, to the accurate
placement of anchors during the deployment and to the forces
applied on the band to reduce annular dimensions. The
CardioBand device has been designed to be applicable to both
type I and IIIb mitral valve dysfunction, although in the latter
case, it could be used in combination with other devices such as
the MitraClip.
Examination of anterior and posterior mitral leaﬂets from all
implanted animals in this study was unremarkable. Similarly, no
device-related microscopic changes were observed in the left,
right or septal heart sections from any animal in the study.
No circumﬂex artery injury was observed in the study, mainly
because the helix anchors are implanted in the base of the left
ventricle, with a direction perpendicular to the annular plane,
towards the apex of the ventricle and far from the atrioventricu-
lar groove. None of the anchors was in the proximity of the cir-
cumﬂex coronary artery nor the coronary sinus.
Imaging guidance
As with other transcatheter techniques, image guidance in the
animal model remains a great challenge. In animals, the most re-
liable imaging technology is epicardial and intracardiac echocar-
diography [9], since transoesophageal echocardiography is not
feasible in most animals due to the interposition of a lung lobe
between the heart and the oesophagus. In our model, imaging
guidance by epicardial echocardiography has been excellent in
the area between the posteromedial commissure and the mid
portion of the posterior annulus, while images became insufﬁ-
cient for safe guidance in the remaining portions of the annulus.
We attempted intracardiac echocardiography to guide some
procedures, but without success. While echocardiography is ne-
cessary to identify the left heart structures, ﬂuoroscopy remains
mandatory to monitor device manipulation since three-
dimensional (3D) echocardiography is not possible in the animal
model. In the future, ﬂuoroscopic guidance may integrate 3D re-
construction capabilities; however, differently from the aortic
valve implantation, the mitral valve structures are more mobile,
Table 1: Echocardiographic findings
Pre-implant vs Post-implant vs Post adjustment
Area (diastolic), cm2 9.8 ± 2.14 P < 0.0001 8.0 ± 2.0 P < 0.0001 6.7 ± 1.7
CC (systolic), mm 3.5 ± 0.4 P < 0.0001 3.2 ± 0.3 P < 0.0001 2.9 ± 0.3
SL (systolic), mm 2.5 ± 0.4 P < 0.0001 2.2 ± 0.4 P = 0.0002 2.1 ± 0.4
Area (diastolic): diastolic cross-sectional area measured at the short-axis epicardial view; CC (systolic): annular systolic intercommissural distance measured
at the short-axis epicardial view; Annular SL (systolic): systolic septo-lateral distance measured at the short axis epicardial view.
Figure 4: Gross anatomy ﬁndings of animals implanted with CardioBand system (a); healing of the CardioBand within the mitral annulus (b).
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and fusion imaging could not be sufﬁciently precise to guide
interventions. Therefore, more sophisticated imaging technolo-
gies using tagging or 3D geonavigation may become necessary.
Integrated CARTO system and intracardiac echocardiography are
a promising technology to help complex structural heart inter-
ventions; however, this has only been tested in electrophysiology
ablation therapies, and may not be appropriate for mitral valve
interventions [10].
At present, live 3D echocardiography is the gold-standard
imaging guidance for structural heart interventions including the
MitraClip therapy [11, 12]. Three-dimensional echocardiography
allows intuitive reconstructions of the anatomy, as well as multi-
plane and X-plane imaging to focus on speciﬁc anatomical
targets. It is expected that the same imaging technology could
be efﬁciently used to guide the CardioBand implantation in
humans, although this requires a dedicated trial. We believe that
the use of transoesophageal 3D echocardiography in the human
will eliminate the limitations of the imaging observed in the
animal model.
CardioBand vs other transcatheter annuloplasty
solutions
CardioBand is the only transcatheter device reproducing the sur-
gical implantation of an annuloplasty device. However, alterna-
tive transcatheter annuloplasty solutions are currently under
investigation.
Kawata et al. developed a direct access transatrial mitral
valve suture annuloplasty technique on the beating-heart
under real-time 3D echocardiography guidance. The authors
used a commercially available suturing device (Sutur Tek Endo
360-degree, Sutur Tek Inc., North Chelmsford, MA, USA) in an
isolated porcine heart model. The suturing device was inserted
through the left atrium. A De Vega-type [13] suture annulo-
plasty was performed under echo guidance. The number of
tissue bites was 7.4 ± 0.8 and the total procedure time was
9.4 ± 2.4 min [14].
Coronary sinus devices have extensively been tested in pre-
clinical as well as in clinical trials [15–21]. Although the concept
of annular remodelling with a coronary sinus implant is attractive
for the simplicity of the procedure, clinical results are still not
convincing. The main limitations of coronary sinus devices are
the anatomical variability of the coronary sinus (atrialization and
distance from the mitral annulus) as well as the risk of compres-
sion of the circumﬂex artery [16].
Annular remodelling has been attempted also using thera-
peutic ultrasound. Jilaihawi et al. [22] reported the animal experi-
ence with the ReCor device (ReCor Medical, Inc., Ronkonkoma,
NY, USA): a 12F balloon catheter was advanced into the left
atrium with a transseptal approach and inﬂated with
contrast-saline, positioned at the mitral annulus, and ultrasound
energy was delivered circumferentially, to heat the annular
tissue. Relative to baseline, the reduction in mitral valve annular
diameter was 8.4% immediately post-procedure (P < 0.001), and
10.8% at 4 weeks (P < 0.001). Histology showed tissue thickening
at the annular level. The risk of coronary artery lesions, as well as
shrinking of native leaﬂets, is still unknown.
Goel et al. [23] reported similar results utilizing radiofrequency
(RF) energy to heat and shrink the mitral valve annulus in an
animal model with a proprietary device (QuantumCor, Lake
Forest, CA, USA) that conforms to the annular shape to deliver
RF energy via a standard generator to replicate a surgical mitral
annular ring. The mean septolateral annular distance was
reduced by a mean of 23.8%. Acute histopathology demon-
strated no damage to the leaﬂets, coronary sinuses or coronary
arteries.
There are two devices designed to directly act at the annular
level, similar to the CardioBand: the Mitralign (Mitralign,
Tewksbury, MA, USA) and the Accucinch (Guided Delivery
Systems, Santa Clara, CA, USA) [24].
Both devices are designed to implant anchors in the subvalvar
area, near to the annulus, and to induce the annular size reduc-
tion by cinching the implanted anchors. While the Accucinch is
designed to deliver multiple anchors along the full length of the
posterior annulus, Mitralign is designed to implant anchors more
selectively, similar to a Key procedure. Compared with the
CardioBand approach, both systems require a retrograde ap-
proach to the mitral valve, which is likely to be less well toler-
ated, particularly in the case of depressed left ventricular
function, due to the crossing of the aortic valve and to the po-
tential for arrythmias. The antegrade approach, on the other
hand, is known to be very well tolerated even in the setting of
severely depressed ventricular function as demonstrated by
Mitraclip implant in end stage failure [25].
In conclusion, the CardioBand system is the ﬁrst device devel-
oped to strictly reproduce surgical annuloplasty. While the
device functioned properly in the animal model, we experienced
the lack of appropriate image guidance using epicardial echocar-
diography. Future studies are needed to experiment alternative
imaging modalities, as well as to test the device in a diseased
animal model to conﬁrm safety and efﬁcacy of transcatheter
annuloplasty.
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APPENDIX. CONFERENCE DISCUSSION
Dr G. Lutter (Kiel, Germany): A new transcatheter mitral valve annuloplasty
system was designed to implant a Dacron band to the posterior leaﬂet to
perform annuloplasty on the beating heart with a sutureless technique, under
echocardiographic and ﬂuoroscopic guidance. So this is certainly a break-
through towards minimally invasive mitral valve repair due to the fact that it
strictly reproduces surgical annuloplasty. I have two questions and one
remark. Can you elaborate a little bit about why you used a posterior band
application solely? An anterior annuloplasty band might have had more effect
in a diseased patient or model.
And secondly, can you give us more details on the repositionability and re-
trievability of your system so that we know how easy it is to act from the
outside in the left atrium. Later on, I mean, you have shown here already a
human case which is very good.
And third, the feasibility in an animal model has been demonstrated in
your pigs. Although the initial minimally invasive procedure was successful,
several challenges, as you have mentioned, such as imaging or a mitral regur-
gitation model, have to be overcome to proceed further in humans. You
might have also some ideas on that.
Dr Maisano: This device has been designed from the beginning to be
completely implantable in the beating heart in a closed heart fashion. The ﬁx-
ation elements are obviously different from sutures and they have to be
implanted deep into the muscle to be effective. So obviously, we cannot use
the same ﬁxation elements in the aorto-mitral continuity. Therefore we
decided, for simplicity and for safety, to develop the ﬁrst-generation devices
as posterior annuloplasty bands. Obviously, with similar technology, you can
also achieve a complete annuloplasty ring. But you should consider different
ﬁxation methods for the anterior portion of the ring itself.
In terms of retrievability and repositionability, all ﬁxation elements are fully
repositionable until they are ﬁnally deployed. They can also be retrievable at
the end of the procedure. If you decided in the middle of the procedure to
bail out, there is a device to literally unscrew all the ﬁxation elements.
Obviously, it would be a complex procedure.
The third question was related to the animal model. We are working on
healthy animals with no MR, because I don’t think we need to demonstrate
that annuloplasty works to ﬁx MR, and the only real challenge we have found
in this, as in many other projects, is image guidance. Image guidance is par-
ticularly critical in the animals. And we have pretty good imaging of the
annulus from the posterior medial commissure to about P2, and very sub-
optimal imaging from P2 to the antero-lateral commissure with any different
imaging modality. We have used epicardial echo TEE, as well as intracardiac
echo, but with all kind of echo-based systems, we have some ﬂaws.
However, the Leipzig group is actively working to incorporate image guid-
ance using ﬂuoroscopy, which will probably solve most of these issues.
Additionally, we expect from the human trial to learn more about the use of
3-D echo for guidance of such procedures.
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